Nicole R van Veenendaal1, Scott A Rivkees. 1. Pediatric Endocrinology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Abstract
CONTEXT: Little information is available about changes in body weight and body mass index in children before, during, and after treatment for Graves' disease (GD). OBJECTIVE: Our objective was to examine changes in body weight after treatment for GD in children as related to clinical features. DESIGN: The medical records of 43 pediatric patients with GD [35 girls and eight boys, aged 4.0-18.5 (mean 10.9) yr] were examined. Patients were included if clinical data were available for 1 yr before and after the diagnosis of GD. MAIN OUTCOME MEASURES: Weight, height, body mass index (BMI) z-scores, and thyroid hormone levels were assessed. RESULTS: Overall, patients presented with an average BMI z-score of -0.02 ± 1.05 that was not different from the normal population (P = 0.921) or their premorbid values (P = 0.07). However, in the subset of patients who were initially overweight or obese in the premorbid state, the BMI decreased significantly during the development of hyperthyroidism (P < 0.05). After initiation of treatment, patients gained significant amounts of weight over the first 6 months leading to elevated BMI z-scores (P < 0.0001), and elevations in BMI persisted in about 25% of the patients. CONCLUSION: Excessive weight gain within 6 months of treatment is seen in children treated for GD, and the gain in weight can persist.
CONTEXT: Little information is available about changes in body weight and body mass index in children before, during, and after treatment for Graves' disease (GD). OBJECTIVE: Our objective was to examine changes in body weight after treatment for GD in children as related to clinical features. DESIGN: The medical records of 43 pediatric patients with GD [35 girls and eight boys, aged 4.0-18.5 (mean 10.9) yr] were examined. Patients were included if clinical data were available for 1 yr before and after the diagnosis of GD. MAIN OUTCOME MEASURES: Weight, height, body mass index (BMI) z-scores, and thyroid hormone levels were assessed. RESULTS: Overall, patients presented with an average BMI z-score of -0.02 ± 1.05 that was not different from the normal population (P = 0.921) or their premorbid values (P = 0.07). However, in the subset of patients who were initially overweight or obese in the premorbid state, the BMI decreased significantly during the development of hyperthyroidism (P < 0.05). After initiation of treatment, patients gained significant amounts of weight over the first 6 months leading to elevated BMI z-scores (P < 0.0001), and elevations in BMI persisted in about 25% of the patients. CONCLUSION:Excessive weight gain within 6 months of treatment is seen in children treated for GD, and the gain in weight can persist.
Authors: H Pijl; P H de Meijer; J Langius; C I Coenegracht; A H van den Berk; P K Chandie Shaw; H Boom; R C Schoemaker; A F Cohen; J Burggraaf; A E Meinders Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Claire L Wood; Niamh Morrison; Michael Cole; Malcolm Donaldson; David B Dunger; Ruth Wood; Simon H S Pearce; Timothy D Cheetham Journal: Eur Thyroid J Date: 2022-01-01
Authors: Christiaan F Mooij; Timothy D Cheetham; Frederik A Verburg; Anja Eckstein; Simon H Pearce; Juliane Léger; A S Paul van Trotsenburg Journal: Eur Thyroid J Date: 2022-01-01